SALT LAKE CITY, UT, UNITED STATES, March 16, 2026 /EINPresswire.com/ -- The National Psoriasis Foundation (NPF) will ...

The FDA granted the approval following findings from the pivotal POETYK PsA-I and POETYK PsA-II Phase III studies.

Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the landmark TOGETHER-PsO open-label Phase 3b clinical trial evaluating the concomitant use of Taltz (ixekizumab) and ...

Ilumya has secured marketing authorisations from more than 55 health authorities worldwide.

Dual therapy with a GLP-1 receptor agonist plus ixekizumab demonstrates long-term benefits in psoriatic disease activity, ...

A simulated analysis in psoriasis highlights divergent patient and payer incentives and inconsistent coverage strategies behind barriers to phototherapy uptake.

What medication clears up plaque psoriasis and is recommended by most dermatologists, but also can’t be defeated or understood, has cropped up periodically throughout human history and is unaffecte | ...

Scott Gottlieb, MD, discusses the real-world outcomes of tildrakizumab for moderate to severe plaque psoriasis.

Portia has not taken Sotyktu. Portia Brown* has long been drawn toward helping people cope with challenges. Since volunteering as a college student to work with her peers to educate them about sexual ...

The product was developed especially for skin prone to psoriasis and is intended to help reduce flaking, roughness and the ...

Psoriasis can easily be mistaken for other difficult-to-deal-with skin problems, like a bad infection or rash, eczema, or dermatitis. And because it varies in severity, it can be tricky to figure out ...